Premium
Patient characteristics, prognostic factors and outcome of dogs with high‐grade primary mediastinal lymphoma
Author(s) -
Moore E. L.,
Vernau W.,
Rebhun R. B.,
Skorupski K. A.,
Burton J. H.
Publication year - 2018
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/vco.12331
Subject(s) - medicine , vincristine , lymphoma , chop , lethargy , polyuria , cyclophosphamide , prednisone , gastroenterology , chemotherapy , oncology , surgery , diabetes mellitus , endocrinology
The goals of this retrospective study were to determine the patient characteristics of dogs with high‐grade primary mediastinal lymphoma and to determine outcome and associated prognostic factors. A total of 42 dogs were identified, in which 36 received treatment and had follow‐up information available. The most common clinical signs included lethargy, anorexia and polyuria/polydipsia. Hypercalcemia and pleural effusion were common findings at diagnosis. The phenotype was almost exclusively T‐cell, most often in association with lymphoblastic cytomorphology as defined by the World Health Organization ( WHO ) lymphoma classification scheme. The overall progression‐free survival ( PFS ) and overall survival ( OS ) were 133 and 183 days, respectively. Treatment with a CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) protocol was associated with an improved PFS (144 days) and OS (194 days) when compared with dogs that received other medical therapies ( P = .005 and P = .002, respectively); the absence of pleural effusion at diagnosis was associated with an increased OS but not PFS . These results suggest that while the prognosis for dogs with mediastinal lymphoma is poor, survival may be improved with treatment using a CHOP ‐based protocol.